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ABSTRACT.
Purpose: To examine the anti-inﬂammatory eﬃcacy and tolerance between
preservative-free dexamethasone (DEX) and diclofenac (DICL) eye drops, and
their combination following cataract surgery.
Methods: A randomized, double-blind, prospective single-centre study with 189
eyes of 180 patients undergoing routine cataract surgery. Laser ﬂare meter
measurement and spectral-domain optical coherence tomography imaging were
conducted before surgery and at the 28-day postoperative visit. Clinical
characteristics, surgical parameters and assessment of postoperative symptoms
were recorded.
Results: Preoperative ﬂare was 9.0  0.6 pu/ms and central retinal thickness
(CRT) 269.6  1.9 lm (mean  SEM). On day 28, ﬂare was 22.1  2.9 pu/ms
for DEX, 17.4  2.5 pu/ms for DICL and 13.0  1.6 pu/ms (p < 0.05) for
their combination. Central retinal thickness (CRT) increase was 31.5  8.8 lm
for DEX, 6.0  0.8 lm (p = 0.001) for DICL, and 3.5  0.5 lm (p < 0.001)
for their combination. The incidence of ocular symptoms related to the eye drops
was 11% for DEX, 37% for DICL and 34% for their combination (p < 0.001).
Clinically signiﬁcant pseudophakic cystoid macular oedema (PCME) was
observed in seven eyes which were all treated with DEX (p < 0.001).
Conclusion: Diclofenac (DICL), as well as the combination of DEX and DICL,
were superior to DEX monotherapy in minimizing CRT change and the incidence
of PCME. Combination medication showed no added value compared to DICL
monotherapy in uneventful cataract surgery.
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Introduction
Postoperative management of cataract
surgery has been a topic of discussion
for a decade. The main interest revolves
around the question whether the choice
between topical corticosteroids or
nonsteroidal anti-inﬂammatory drug
(NSAID) aﬀects postoperative inﬂam-
mation or the risk of developing pseu-
dophakic cystoid macular oedema
(PCME; also, known as Irvine–Gass
syndrome), and whether the choice has
an impact on the speed of visual recovery
and acuity gain. In addition, concerns of
drug tolerability diﬀerences between
NSAIDs and corticosteroids have
emerged (Duong et al. 2014; Kessel et
al. 2014; Kim et al. 2015; Cardascia
et al. 2016; Coassin et al. 2016; Grzy-
bowski et al. 2016;Limet al. 2016;Malik
et al. 2016; Duan et al. 2017; Pollack
et al. 2017).
The measurement of aqueous ﬂare,
using automated laser ﬂare metering
technology, has enabled objective eval-
uation of anterior chamber reaction for
postoperative inﬂammation. Excess
sterile intraocular postoperative inﬂam-
mation and breakdown of the blood–
retinal barrier as marked by aqueous
ﬂare have been shown to be connected
with the risk for PCME (Ersoy et al.
2013). Widespread use of optical coher-
ence tomography (OCT) has facilitated
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highly sensitive detection and follow-
up of central retinal thickness (CRT)
increase, which correlates with PCME
development (Kusbeci et al. 2012).
Prior studies deﬁne a 30% increase in
central thickness on OCT as a diag-
nostic sign for PCME (Kim et al. 2007;
Singh et al. 2012; Pollack et al. 2017).
The data on eﬃcacy in the manage-
ment of anterior chamber inﬂamma-
tion between topical corticosteroids
and NSAID remain conﬂicting; how-
ever, the choice of NSAID may result
in less PCME (Henderson et al. 2007;
Kim et al. 2010; Duong et al. 2014;
Kessel et al. 2014; Wielders et al. 2015;
Grzybowski et al. 2016; Malik et al.
2016; Duan et al. 2017). Prior random-
ized clinical trials often lack head-to-
head comparison between the most
potent corticosteroid and NSAID eye
drops in prevention of PCME (Shi-
mura et al. 2007; Miyake et al. 2011).
The choice for patients at increased
risk of PCME, such as those with
diabetes, with or without retinopathy
(Zaczek et al. 1999; Somaiya et al.
2002; Kim et al. 2007; Chu et al.
2016), seems to include a combination
of corticosteroids and NSAID (Hen-
derson et al. 2007; Singh et al. 2012;
Pollack et al. 2017). The combination
of corticosteroids and NSAID results
in lower PCME incidence when com-
pared to topical corticosteroids, as well
as with uneventful surgery for nondia-
betic patients (Wolf et al. 2007; Wield-
ers et al. 2015).
Indeed, despite growing number of
studies and meta-analyses, assessment
of clinical care guidelines for postoper-
ative medication congruent with the
study outcomes in uneventful cataract
surgery remains a challenge. Multiple
treatment protocols, even within a
single unit, are common. Here, we
aimed to determine the tolerability
and compliance, and the eﬀectiveness
for postoperative aqueous ﬂare and
PCME between a potent treatment
with topical preservative-free dexam-
ethasone (DEX), diclofenac (DICL),
and a combination of these regimens.
Materials and Methods
Study design
This study was conducted as a random-
ized, double-blind, prospective single-
centre study. Patients were admitted as
per the national guidelines for the
management of cataract in the Depart-
ment of Ophthalmology, Kymenlaakso
Central Hospital, Kotka, Finland. A
total of 224 eyes of 214 patients sched-
uled for cataract surgery were enrolled
between January 2016 andOctober 2016
for either preservative-free corticos-
teroid (Monopex, DEX phosphate
1 mg/ml; Laboratoires Thea, Cler-
mont-Ferrand, France), or NSAID
(Voltaren Ophtha, DICL sodium
1 mg/ml; Laboratoires Thea) eye drops,
or a combination of these two drugs.
The patients were examined by an
ophthalmologist preoperatively on the
operation day and the patients visited a
research technician at the 28th postop-
erative day (2 days). On both visits,
aqueous ﬂare and mean CRT were
recorded by a laser ﬂare meter (FM-
600; Kowa Company, Ltd., Nagoya,
Japan) and spectral-domain OCT (Hei-
delberg Eye Explorer Version 1.9.10.0
and HRA/SPECTRALIS Viewing
Module Version 6.0.9.0; Heidelberg
Engineering GmbH, Heidelberg,
Germany), respectively.
At the 28-day control visit, a ques-
tionnaire for regularity of eye drop use,
adverse eﬀects of topical medication,
subjective visual recovery and overall
satisfaction of participants were docu-
mented by the interview of the research
technician. The primary outcomes were
anterior chamber ﬂare at 28 days and
change in CRT between measurements.
Secondary outcomes were visual acuity
(VA) gain and subjective irritation
symptoms.
The study was conducted according
to the tenets of the Declaration of
Helsinki and was approved by the Fin-
nish Medicines Agency Fimea and the
Institutional Review Board of Helsinki
University Hospital (EudraCT Num-
ber: 2015-003296-30). Written consent
was obtained from each participant
(except for one patient giving oral con-
sent for not being able to write) before
enrollment in the study. Conﬁdentiality
of the patient records was maintained
when the clinical data were entered into
a computer-based standardized data
base for analysis.
Patients
A total of 224 eyes of 214 patients
scheduled for cataract surgery were
enrolled between January 2016 and
October 2016. Thirteen patients did
not want to continue in the research
and gave no speciﬁc reason or could
not attend the predetermined control
visit within 2 days. Five patients left
the study group because they had
symptoms from the eye drops and their
medication was changed. Ten subjects
did not use the medications as pre-
scribed (oral and written instructions
were given), and two subjects had mild
corneal oedema which led to changes in
medication. On a later review, ﬁve
patients were found not to ﬁll the
inclusion/exclusion criteria to the
study; one patient (DEX group) did
not meet the age criterion, one patient
(DEX) was revealed to have wet age-
related macular degeneration (AMD),
two patients (DEX) had iris prolapsed
during surgery and one patient
(DEX + DICL) was found to have an
old branch retinal vein occlusion. Base-
line variables were evaluated according
to intention to treat (Tables 1 and 2)
and per protocol (Tables S1 and S2)
analysis. After these dropouts, a total
of 189 eyes of 180 patients were
included in the analysis (Fig. 1).
Randomization
The study was conducted as a random-
ized, double-blind, prospective single-
centre study (hrrg.ﬁ/en/clinicaltrials/
cataract/). The patients were randomized
into three groups for postoperative
anti-inﬂammatory medication: (i) preser-
vative-free corticosteroid eye drops
(Monopex, DEX phosphate 1 mg/ml;
Laboratoires Thea) three times a day
(t.i.d.) for 3 weeks; (ii) preservative-free
NSAID eye drops (Voltaren Ophtha,
DICL sodium 1 mg/ml; Laboratoires
Thea) t.i.d. for 3 weeks; or (iii) a combi-
nation of both drops with similar dosing.
Nopreoperativeanti-inﬂammatorydrops
were used.
The drug pipettes were covered with
tape by hospital pharmacy and put into
marked envelopes. After the cataract
operation, the research technician ran-
domized the operated patient into a
study group and distributed the
marked envelopes accordingly. The
blinding was uncovered after the data
was analyzed.
Inclusion criteria
The study subjects were aged 60–
90 years and were eligible for cataract
surgery under the Current Care Guide-
lines of Cataract Surgery of the Finnish
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Medical Society, Duodecim (updated
in year 2013).
Exclusion criteria
Exclusion criteria of the study were
prior or active wet AMD, retinal vein/
artery occlusion, retinal detachment,
retinal necrosis, vitritis/endophthalmi-
tis, vitreous haemorrhage, retinal phle-
bitis or optic neuritis, previous
intraocular procedures (including fun-
dus laser photocoagulation), planned
anti-vascular endothelial growth factor
treatments, myopia above 6.0 diop-
tres, alcohol abuse, hypothyroidism
with thyroid-stimulating hormone
(TSH) above physiological range, con-
tinuous use of anti-inﬂammatory drugs
and sensitivity to any of the medica-
tions used in the operation or postop-
eratively. Intraoperative complications
such as iris prolapse, use of sutures or
posterior capsule tear, failure to attend
the postoperative control visit at
28  2 days and failure to use the
postoperative anti-inﬂammatory medi-
cation as prescribed were criteria for
exclusion. Prior enrollment of con-
tralateral eye was not considered as
an exclusion criterion. However, (i) no
simultaneous bilateral cataract
surgeries were performed to study
patients, (ii) randomization of treat-
ment group was performed before
every surgery independently from prior
contralateral eye surgery and (iii) the
minimum gap between the surgeries
was 1 month giving suﬃcient time to
recover from the ﬁrst surgery.
Surgery
A standardized phacoemulsiﬁcation
technique was used in all cataract surg-
eries (hrrg.ﬁ/en/videos/cataract/). Cat-
aract surgeries were performed by three
specialists and three experienced resi-
dents in ophthalmology. A 2.75 mm
clear cornea incision was followed by
capsulorhexis, phacoemulsiﬁcation (di-
vide and conquer) and intraocular lens
placement into the capsular bag. An
Ozil phacoemulsiﬁcation handpiece and
a 0.9 mm 30-degree beveled Kelman tip
were used in the phacoemulsiﬁcation
system (Inﬁniti; Alcon, Fort Worth,
TX, USA). In all cases, anaesthesia was
topical. Hyaluronic acid 1.6%-chon-
droitin sulphate 4.0% (DisCoVisc;
Alcon) was used as ophthalmic visco-
surgical device. Preloaded aspheric
hydrophobic single-piece monofocal
intraocular lenses were used (PCB00,
Tecnis IOL in iTec delivery system;
AbbottMedical Optics Inc., Santa Ana,
CA, USA; AU00T0, AcrySof IQ,
SN60WF in UltraSertTM delivery sys-
tem; Alcon). Antimicrobial medication
included intraoperative intracameral
cefuroxime (Aprokam, Laboratoires
Thea) and postoperative levoﬂoxacin
5 mg/ml eye drops t.i.d. for 1 week
(Oftaquix; Santen Pharmaceutical
Co. Ltd, Osaka, Japan). Duration of
operation, phaco energy (cumulative
dissipated energy; CDE) and use of
intraocular surgical aid (StabilEyes
capsular tension ring (CTR); Abbott
Medical Optics Inc., 6.25 mmMalyugin
Ring pupil extension device; Micro-
Surgical Technology, Redmond, WA,
USA) were recorded.
Clinical evaluation
Biometry was evaluated at the day of
surgery using swept-source optical
coherence tomography (SSOCT) tech-
nology (OA-2000; Tomey GmbH,
N€urnberg Germany) (McAlinden et al.
2017).
Best-corrected visual acuity (BCVA)
was preoperatively evaluated by the
referring ophthalmologist and postop-
eratively with an autorefractometer
Table 2. Surgical variables (intention to treat analysis).
DEX (n = 78) DICL (n = 78) DEX + DICL (n = 68)
Operation time (min) 19.2  1.2 (7–75) 19.1  1.3 (5–70) 21.7  1.3 (6–56)
Phaco energy (CDE) 17.2  1.0 (5.6–43.2) 17.6  1.0 (6.3–51.3) 20.7  1.6 (5.4–68.4)
Pupil extension device n/% 10 (13%) 6 (9%) 4 (6%)
CTR n/% 3 (4%) 1 (1%) 1 (1%)
Baseline variables regarding surgical parameters. Data are given as mean (SEM) and range or absolute number and proportion.
CDE = cumulative dissipated energy, CTR = capsular tension ring, DEX = dexamethasone, DICL = diclofenac.
Table 1. Baseline variables (intention to treat analysis).
DEX (n = 78) DICL (n = 78) DEX + DICL (n = 68)
Gender (M/F) n/% 36:42 (46:54%) 30:48 (38:62%) 25:43 (37:63%)
Age (years) 77.1  0.8 (63–96) 76.0  0.7 (62–88) 76.2  0.9 (62–90)
Diabetes n/% 15 (19%) 17 (22%) 12 (18%)
Smoking n/% 10 (13%) 5 (6%) 5 (7%)
BCVA (Snellen decimals) 0.32  0.02 (<0.1–0.70) 0.37  0.02 (<0.1–1.00) 0.36  0.02 (<0.1–0.80)
IOP (mmHg) 15.4  0.4 (8–22) 16.8  0.5 (7–32) 16.0  0.5 (9–32)
PFX n/% 17 (22%) 15 (19%) 10 (15%)
CRT mean (lm) 270.7  3.9 (177–415) 275.6  3.0 (228–374) 264.7  3.4 (208–378)
AMD n/% 22 (28%) 24 (31%) 21 (31%)
iERM (pucker) n/% 6 (8%) 7 (9%) 2 (3%)
Baseline variables regarding (i) patient (ii) ophthalmic (iii) posterior segment and parameters. Data are given as mean (SEM) and range or absolute
number and proportion.
AMD = age-related macular degeneration, BCVA = best-corrected visual acuity, CRT = mean central retinal thickness, DEX = dexamethasone,
DICL = diclofenac, iERM = idiopathic epiretinal membrane, IOP = intraocular pressure, PFX = pseudoexfoliation syndrome.
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(AR-1s; NIDEK Co. Ltd, Aichi,
Japan) at standardized light condi-
tions. Intraocular pressure (IOP) was
measured by rebound tonometry
(iCare tonometer; Revenio Group,
Vantaa, Finland) to rule out diﬀerences
regarding IOP adverse eﬀects between
the tested groups.
Follow-up 30-frame scans were per-
formed with AutoRescanTM software,
and preoperative OCT analyses were
compared to those obtained 28 days
after surgery (Heidelberg Eye Explorer
Version 1.9.10.0 and HRA/SPECTRA-
LIS Viewing Module Version 6.0.9.0;
Heidelberg Engineering GmbH).
Aqueous ﬂare was measured preop-
eratively and at 28-day postoperation
with a laser ﬂare meter (FM-600; Kowa
Company, Ltd.). The mean of ﬁve
reliable measurements was used in the
analysis.
The diagnosis for PCME was based
on clinical appearance together with
typical OCT ﬁndings taken at the
28-day control visit (Antcliﬀ et al.
2000; Kusbeci et al. 2012).
Power analysis
The power analysis was based on
sample size estimate for aqueous ﬂare
as it required higher number of
enrolled patients than the second pri-
mary outcome, change in CRT. Aqu-
eous ﬂare at day 28 was estimated 10
(A)
(B)
Fig. 1. Per protocol analysis and outcome measures between study groups (A) Study ﬂow chart and (B) subjective symptoms from anti-inﬂammatory
drops, delayed visual recovery, PCME, BCVA at day 28 and overall satisfaction. BCVA = best-corrected visual acuity, PCME = pseudophakic
cystoids macular oedema.
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photons/ms for the DICL group and
12 photons/ms for the DEX group with
standard deviation 15 for both. Non-
inferiority margin was set at 5 with
80% power and sampling ratio 1:1. The
sample size estimated at 57 for single
group adding to 71 with 25% estimated
dropout rate. It was safe to assume
similar diﬀerence will be detected for
the inferior product comparing to com-
bination treatment.
Statistical analyses
Data are given as mean  SEM, except
for the absolute numbers and propor-
tions for the nominal scale. IBM SPSS
Statistics 24 (SPSS Inc., Somers, NY,
USA) was used for statistical analysis.
For two-group comparisons, data were
analysed for continuous variables with
Student’s t-test and nonparametric
Mann–Whitney U-test for groups with-
out normal distribution. Multiple
groups were compared with the one-
way ANOVA test using Bonferroni cor-
rection. Qualitative data were analyzed
with the two-factor chi-squared test or
Fisher–Freeman–Halton test for multi-
ple groups. A linear regression model
was used to estimate the relationships
between variables. p ≤ 0.05 was consid-
ered statistically signiﬁcant.
Results
Baseline variables
Baseline variables were comparable
between DEX, DICL and combination
treatment groups regarding (i) patient
(gender, age, smoking), (ii) ophthalmic
[BCVA, CRT, IOP, pseudoexfoliation
syndrome(PFX)], (iii) posterior segment
[existence of AMD and epiretinal mem-
brane (macularpucker)] and(iv) surgical
characteristics [operation time, phaco
energy (CDE), aid of pupil expansion
devices and CTRs; p = NS, Tables 1
and 2].
Subjective irritation symptoms reported
from anti-inﬂammatory medication
Subjective symptoms, visual recovery
and overall satisfaction were docu-
mented at 28-day postoperative visit
using a structured questionnaire and
interview by research technician. In 51
of the 189 study eyes (27%), symptoms
were reported from the anti-inﬂamma-
tory eye drops. Seven (11% incidence)
were given topical DEX, 26 (37%) topi-
cal DICL (p < 0.001; Fig. 1B), and 18
(34%) combination of both (p < 0.001;
Fig. 1B). Forty-six of 51 (90%) of these
symptoms were reported as stinging/
burning sensation, one reporting symp-
toms in visual ﬁeld after administering
medication (DICL), one reporting pain
after administering medication (DEX
+ DICL), three not being able to specify
the symptom (1 DEX and 2 DICL).
Twenty-two of the 189 study eyes
(12%) were reported to having taken a
week or more for VA to rise to its
eventual postoperative state. Eleven
(17% incidence) were treated with
topical DEX, six (9%) topical DICL,
and ﬁve (9%) the combination of both
(p = NS; Fig. 1B). Patient satisfaction
survey (grade 1–10) revealed satisfac-
tion grade 9.21  0.16 in those receiv-
ing DEX, 9.43  0.09 in those
receiving DICL, and 9.14  0.15 in
those receiving combination treatment
(p = NS; Fig. 1B).
Effect of anti-inﬂammatory medication on
aqueous ﬂare
Compared to the day of surgery, aque-
ous ﬂare increased by 11.4  2.6 pu/ms
in DEX, 9.0  2.5 pu/ms in DICL and
3.6  2.2 pu/ms in the combination
group (p = NS; Fig. 2A). At day 28,
aqueous ﬂare was 22.1  2.9 pu/ms in
DEX, 17.4  2.5 pu/msec in DICL and
13.0  1.6 pu/ms (p = 0.042; Fig. 2B)
in the combination group.
Effect of anti-inﬂammatory medication on
central retinal thickness
Central retinal thickness (CRT) increase
was 31.5  8.8 lm in DEX, 6.0 
0.8 lm in DICL (p = 0.001; Fig. 3A)
and 3.5  0.5 lm in the combination
group (p < 0.001; Fig. 3A). At day 28,
CRT was 302.3  9.9 lm in DEX,
281.1  3.2 lm in DICL (p = 0.047;
Fig. 3B) and 266.4  3.1 lm in the com-
bination group (p < 0.001; Fig. 3B).
(A) (B)
Fig. 2. The eﬀect of anti-inﬂammatorymedication on aqueous ﬂare. (A) Change in aqueous ﬂare and
(B) aqueous ﬂare at 28 days after uncomplicated cataract surgery. DEX = dexamethasone, DEX
DICL = dexamethasoneanddiclofenac combination treatment,DICL = diclofenac, pu/msec = pho-
ton units per millisecond. *p < 0.05.
(A) (B)
Fig. 3. The eﬀect of anti-inﬂammatory medication on CRT. (A) Change in CRT and (B) CRT at
28 days after uncomplicated cataract surgery. CRT = central retinal thickness, DEX = dexam-
ethasone, DEX DICL = dexamethasone and diclofenac combination treatment, DICL = diclofe-
nac. *p < 0.05, **p = 0.001, ***p < 0.001.
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Visual acuity gain in patients with and
without pseudophakic cystic macular
oedema
At day 28, BCVA was 0.83  0.04
decimal units in DEX, 0.99  0.03
decimal units in DICL (p = 0.006;
Fig. 4A) and 0.93  0.04 decimal units
in the combination group. Best-cor-
rected VA (BCVA) gain was 0.54 
0.04 decimal units in DEX, 0.63  0.04
decimal units in DICL and 0.58  0.04
decimal units in the combination treat-
ment group (p = NS; Fig. 4A).
Clinically, refractory PCME was
observed in seven eyes of seven patients
(amongwhichﬁve eyes hadCRT increase
more than 30%). All seven eyes with
PCME were in the DEX group
(p < 0.001; Fig. 1B). Baseline values in
eyes with and without PCME did not
diﬀer with regard to the patient age
(76.9  3.1 versus 76.3  0.5 years),
gender distribution (3:4 versus 72:110
male:female), smoking (1:6 versus
15:167 smoking:nonsmoking), aqueous
ﬂare (9.4  1.7 versus 9.0  0.6 pu/ms),
CRT (296.3  21.0 versus 268.5  1.8
lm) and IOP (15.2  2.5 versus 16.2 
0.3 mmHg; p = NS; data not shown).
Central retinal thickness (CRT)
increase was 173.4  38.7 lm (+62.2 
14.8%) for those with PCME and
6.6  0.7 lm (+2.5  0.2%) for those
without (p < 0.001, data not shown).
Central retinal thickness (CRT) at
28 days was 469.7  33.6 lm for those
with PCME and 276.3  2.3 lm for
those without PCME (p < 0.001, data
not shown). Best-corrected VA (BCVA)
at day 28 was markedly impaired in the
eyes with PCME from those without
(0.55  0.05 versus 0.93  0.02 deci-
mals, p = 0.001; Fig. 4B).Gain in BCVA
was 0.36  0.09 decimals for those
with PCME compared to 0.59  0.02
for those without PCME (p = 0.060;
Fig. 4B).
Effect of anti-inﬂammatory medication on
intraocular pressure 28 days after cataract
surgery
In the study eyes, at 28 days IOP reduc-
tion was 5.5  0.3 mmHg, the level of
IOP being 10.7  0.2 mmHg. The IOP
change and mean IOP at 28 days was
5.1  0.5mmHgand10.4 0.4mmHg
in DEX, 6.1  0.5 mmHg and 10.9 
0.4 mmHg in DICL, and5.4 0.5 and
10.8  0.4 mmHg in the combination
group (p = NS; Fig. 5A,B).
Effect of patient and ophthalmic variables
on the main outcome measures
In eyes with dry AMD, aqueous ﬂare at
28 days (20.5  3.5 pu/ms) and CRT
increase (8.4  1.8 lm) did not signiﬁ-
cantly diﬀer from the eyes without dry
AMD (16.6  1.4 pu/ms and 15.4 
4.2 lm, respectively, p = NS; data not
shown). Furthermore, in eyes with
macular pucker, aqueous ﬂare at
28 days (27.5  6.7 pu/ms) and CRT
increase (20.3  8.7 lm) were compar-
able to eyes without macular pucker
(19.5  1.5 pu/ms and 12.9  3.1 lm,
respectively, p = NS; data not
shown).
Effect of surgical parameters on the main
outcome measures
Aqueous ﬂare at 28 days and CRT
increase did not correlate with phaco
energy (R2 = 0.019, p = 0.068 and R2
= 0.004, p = 0.391, respectively) nor
operation time (R2 < 0.001, p = 0.938
and R2 = 0.015, p = 0.110, respec-
tively). Eyes with and without PCME
did not diﬀer for phaco energy (19.6 
5.6 versus 18.3  0.7 CDE) nor oper-
ation time (25.4  8.8 versus 19.8
 0.8 min, p = NS; data not shown).
Aqueous ﬂare at 28 days remained
statistically insigniﬁcant between eyes
with pupil expansion device (33.4 
12.7 pu/ms) and CTR (30.2  18.1 pu/
ms) and those without (17.3  1.5 pu/
ms and 16.6  1.4 pu/ms, respectively,
p = NS; data not shown). Further-
more, CRT increase was comparable
between eyes with pupil expansion
device (15.1  5.2 lm) and CTR
(5.8  4.1 lm) and eyes without
(13.1  3.2 lm and 13.5  3.0 lm,
respectively, p = NS; data not shown).
Discussion
Our present results favour topical
NSAIDs over corticosteroids as a ﬁrst-
line choice in postoperative inﬂamma-
tion management. According to our
data, DICL was more eﬀective than
DEX in preventing PCME. To our
knowledge, this is the ﬁrst report inves-
tigating added beneﬁt of combination
(A) (B)
Fig. 4. The eﬀect of anti-inﬂammatory medication and PCME on postoperative BCVA. Best-
corrected visual acuity (BCVA) gain (white bars) and BCVA (colored bars) 28 days after
uncomplicated cataract surgery (A) in eyes treated with diﬀerent anti-inﬂammatory medication
and (B) in eyes with or without PCME. BCVA = best-corrected visual acuity, PCME = pseu-
dophakic cystoid macular oedema. DEX = dexamethasone, DEX DICL = dexamethasone and
diclofenac combination treatment, DICL = diclofenac. **p < 0.01.
(A) (B)
Fig. 5. The eﬀect of anti-inﬂammatory medication on IOP. (A) Change in IOP and (B) IOP at
28 days after uncomplicated cataract surgery. DEX = dexamethasone, DEX DICL = dexam-
ethasone and diclofenac combination treatment, DICL = diclofenac, IOP = intraocular pressure.
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treatment over NSAID monotherapy.
In this sample of patients with unse-
lected cataract, combination therapy of
both topical DEX and DICL presented
better results on primary outcomes over
DEX monotherapy. Combination ther-
apy did not, however, promote added
beneﬁt to DICL monotherapy. Our
data are clinically relevant, considering
that steroid monotherapy is still pri-
mary treatment in many clinics.
The suggested mechanisms contri-
buting to the development of PCME
include increase in vascular permeability
through inﬂammatory mediators such
as prostaglandins (Flach 1998; Kessel
et al. 2014). Corticosteroids prevent
inﬂammationbypleiotropicmechanisms
(including inhibition of prostaglandin
synthesis), whereas NSAIDs speciﬁcally
inhibit prostaglandin production (Kim
et al. 2010). Combination therapy of
corticosteroids and NSAID may oﬀer
limited synergistic anti-inﬂammatory
eﬀects. Comparison between NSAID
and combination therapy in high-risk
groups such as diabetic patientswouldbe
of interest to challenge the hypothesis.
Of note, in this study of patients
with unselected cataract, we chose not
to use preoperative anti-inﬂammatory
medication. In our study population,
age, gender, presence of posterior seg-
ment comorbidities (macular pucker or
dry AMD) and surgical parameters
(use of a CTR or a pupil expansion
device) did not have a signiﬁcant eﬀect
on the change in aqueous ﬂare or CRT.
Furthermore, the operation time or
phaco energy did not aﬀect the change
in aqueous ﬂare or CRT either. Several
known risk factors for PCME were
considered as exclusion criteria for the
study. In high-risk patients, preopera-
tive medication of anti-inﬂammatory
mono or combination therapy may be
warranted (Kessel et al. 2014).
The number of dropouts was some-
what high in relation to the length of
the follow-up. Baseline variables
according to intention to treat gives
an accurate image of successful
randomization (per protocol data pre-
sented as supplement), while follow-up
according to per protocol represents
the study population within the limits
of strict exclusion criterion. Here, the
single major reason for dropout was
failure to attend the control visit on the
postoperative 28  2 days, which we
considered as a strict exclusion
criterion for the study. Patients treated
with DICL or combination therapy
reportedmore irritation symptoms than
those treated withDEXonly. One could
anticipate better compliance among
DEX users when compared to those of
DICL. The number of dropouts was
comparable between DEX, DICL and
combination therapy groups despite the
diﬀerence in tolerability. Ten eyes were
case speciﬁcally excluded due to misuse
of prescribed anti-inﬂammatory regi-
men (regardless detailed instructions
given in oral and written form), while
occasional memory slips were accepted.
Patients seemed to report medication
use accordingly, but chance of report
error and recall bias exists and needs to
be acknowledged.
Another limitation of our study is
the lack of long-term 3–12 months of
follow-up. Our follow-up was only
1 month, which was adopted according
to the Current Care Guidelines of
Cataract Surgery of the Finnish Med-
ical Society, Duodecim (updated in
year 2013). The need for such control
visit as a routine clinical practice was
recently questioned (Eloranta & Falck
2017). However, 1-month control visit
is suitable to pick up prolonged inﬂam-
mation after the course of topical anti-
inﬂammatory treatment. Even though
most cases of refractory PCME occur
later at 4–10 weeks (giving the deﬁni-
tive conclusion regarding incidence of
refractory PCME only after 3 months),
diﬀerences in CRT with modern OCT
imaging are apparent already at
28 days.
During postoperative treatment,
preservative-free products may reduce
ocular discomfort and even exhibit
superior anti-inﬂammatory eﬃcacy
(Maca et al. 2010; Yasuda et al.
2012). Dexamethasone (DEX), among
another potent corticosteroid pred-
nisolone acetate, have been proven
eﬀective in postoperative use (Laurell
& Zetterstr€om 2002; Kessel et al.
2014). Nepafenac has established a
wide market share (Margulis et al.
2017). Lack of suﬃcient data on potent
NSAID head-to-head comparison in
cataract surgery limits establishment of
one drug over another. Keeping in
mind the considerable incidence of
irritation after topical preservative-free
DICL that did not, however, reﬂect as
compliance problems, our ﬁndings
favour choosing DICL instead of
DEX as the ﬁrst-line postoperative
medication after cataract surgery in
preventing PCME, and to reserve DEX
for the combination therapy for
patients with highest risk of postoper-
ative complications. Further studies are
needed to optimize the length of treat-
ment and follow-up, to investigate the
potential of preoperative medication
(Grzybowski et al. 2016) and to eluci-
date the eﬀectiveness, tolerability and
compliance between topical NSAID
regimens.
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